Through a major health platform exclusive collaboration with Marius Pharmaceuticals and more, the company is expanding access to innovative testosterone treatments

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new category in men’s health, offering access to innovative, affordable, and personalized treatment plans for low testosterone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910502249/en/

Through a major health platform exclusive collaboration with Marius Pharmaceuticals and more, the company is expanding access to innovative testosterone treatments.

An estimated twenty million men in the U.S. struggle with low testosterone^{1 2}. Left untreated, it can drain energy, dull mood and sexual desire, and raise risks of heart disease, diabetes, and cancer. Treatment can restore energy, improve sexual function, build muscle and bone strength, and support long-term health. Yet most never receive care due to stigma, outdated treatments, and high costs. Hims & Hers is changing that.

In 2026, Hims & Hers will expand its category offerings with the launch of an exclusive branded oral testosterone through a major health platform exclusive collaboration with Marius Pharmaceuticals, a leader in testosterone therapy innovation. KYZATREX® is a needle-free FDA-approved medication shown to restore testosterone levels in up to 96% of men.³ It also doubles free testosterone⁴, the type of testosterone linked to energy, drive, and performance, all while maintaining a low side effect profile⁵.

“Low testosterone care has been stuck in the past, stigmatized, expensive, and inaccessible for most men,” said Andrew Dudum, founder and CEO of Hims & Hers. “We’re bringing it into the future with treatments that are easy to access and designed around each individual. This isn’t just about one product, it’s about addressing a condition that fundamentally changes how millions of men will feel and show up in life, and about building an entirely new model of care that they can finally rely on.”

“Marius developed KYZATREX® to modernize testosterone replacement therapy with an oral treatment backed by rigorous science and FDA approval,” said Shalin Y. Shah, CEO of Marius Pharmaceuticals. “Partnering with Hims & Hers allows us to bring this innovation to scale. Their platform has proven reach, accessibility, and trust with millions of customers, making them the perfect partner to expand access to KYZATREX® and redefine what’s possible in men’s hormone health.”

Starting today, providers will also be able to prescribe tailored doses of compounded enclomiphene⁶ through the Hims & Hers platform and, for men experiencing sexual symptoms, offer personalized testosterone care that combines enclomiphene and tadalafil in a single dual-action treatment. Enclomiphene restores natural testosterone production, without compromising fertility, and has been shown to double testosterone levels⁷. Customers begin with a simple at-home blood test, receive results in days instead of months, and then work with a licensed provider to find the treatment plan that best fits their needs.

Hims & Hers will also introduce access to injectable testosterone treatments in 2026, giving men even more options for care, all connected through the Hims & Hers digital platform with licensed providers and 24/7 access to support.

For more information, visit https://www.hims.com/testosterone

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Cautionary Note Regarding Forward-Looking Statements:

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to the changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the pricing of any new products or offerings, the timing and anticipated effect of any collaborations, our market opportunity, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, delays in offering development; failure of offerings to perform as expected; limited market acceptance of new offerings; inability to obtain or maintain regulatory approvals; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; competitive product launches; challenges in manufacturing, distribution or supply chain; higher than anticipated launch costs; shifts in consumer spending or behavior; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of September 10, 2025. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.

We may include statements and information in this communication concerning our industry and the markets in which we operate, including our market opportunity, which are based on information from independent industry organizations and other third-party sources (including industry publications, surveys and forecasts). While we believe these third-party sources to be reliable as of the date of this communication, we have not independently verified any third-party information and such information is inherently imprecise.

<sup>__________________________________________

1</sup>Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A., & McWhirter, C. (2006). Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International journal of clinical practice, 60(7), 762–769. https://doi.org/10.1111/j.1742-1241.2006.00992.x

²National Population by Characteristics: 2020-2022. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2020 to July 1, 2022 (NC-EST2022-SYAEXN). U.S. Census Bureau. https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html. Accessed 8/11/23..

³Bernstein, J. S., & Dhingra, O. P. (2024). A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Therapeutic advances in urology, 16, 17562872241241864. https://pmc.ncbi.nlm.nih.gov/articles/PMC11008350/

⁴Bernstein, J. S., & Dhingra, O. P. (2024). A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Therapeutic advances in urology, 16, 17562872241241864. https://pmc.ncbi.nlm.nih.gov/articles/PMC11008350/

⁵KYZATREX [prescribing information]. Raleigh, NC: Marius Pharmaceuticals; 2022

⁶Testosterone Rx is not approved or evaluated for safety, effectiveness, or quality by the FDA. Not available in all 50 states. Prescription products require an online consultation with a healthcare provider who will determine if a prescription is appropriate. See website for full details, important safety information, and restrictions.

⁷Wiehle, R. D., Fontenot, G. K., Wike, J., Hsu, K., Nydell, J., Lipshultz, L., & ZA-203 Clinical Study Group (2014). Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertility and sterility, 102(3), 720–727. https://www.fertstert.org/article/S0015-0282(14)00537-8/fulltext

View source version on businesswire.com: https://www.businesswire.com/news/home/20250910502249/en/